• 1
    Decker DA, Drelichman A, Jacobs J, et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer. 1983; 51: 1353-1355.
  • 2
    Jacobs C, Goffinet DR, Goffinet L, Kohler M, Fee WE. Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer. 1987; 60: 1178-1183.
  • 3
    Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994; 86: 265-272.
  • 4
    Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer. 2000; 83: 1594-1598.
  • 5
    Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol. 2003; 21: 327-333.
  • 6
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Fort Washington, Pa: National Comprehensive Cancer Network; 2007. Available at: Accessed June 9, 2009.
  • 7
    Laccourreye O, Brasnu D, Bassot V, Menard M, Khayat D, Laccourreye H. Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: 5-year results. J Clin Oncol. 1996; 14: 2331-2336.
  • 8
    Laccourreye O, Veivers D, Hans S, Menard M, Brasnu D, Laccourreye H. Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders. Cancer. 2001; 92: 1504-1511.
  • 9
    [No authors listed] Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991; 324: 1685-1690.
  • 10
    Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1995; 71: 83-91.
  • 11
    El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol. 1996; 14: 838-847.
  • 12
    Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996; 88: 890-899.
  • 13
    Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355: 949-955.
  • 14
    Gibson MK, Forastiere AA. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol. 2006; 7: 565-574.
  • 15
    Laccourreye H, Brasnu DF, Beutter P. Carcinoma of the laryngeal margin. Head Neck Surg. 1983; 5: 500-507.
  • 16
    Lefebvre JL, Buisset E, Coche-Dequeant B, et al. Epilarynx: pharynx or larynx? Head Neck. 1995; 17: 377-381.
  • 17
    Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. 6th ed. New York, NY: John Wiley & Sons; 2002.
  • 18
    Warren S, Gates O. Multiple primary malignant tumors. Am J Cancer. 1932; 16: 1358-1414.
  • 19
    Nikolaou AC, Markou CD, Petridis DG, Daniilidis IC. Second primary neoplasms in patients with laryngeal carcinoma. Laryngoscope. 2000; 110: 58-64.
  • 20
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 21
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655.
  • 22
    Woolson RF, Clarke WR. Statistical Methods for the Analysis of Biomedical Data. 2nd ed. New York, NY: John Wiley & Sons; 2002.
  • 23
    Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York, NY: Springer-Verlag; 1997.
  • 24
    Bonfils P, Trotoux J, Bassot V. Chemotherapy alone in laryngeal squamous cell carcinoma. J Laryngol Otol. 2007; 121: 143-148.
  • 25
    Holsinger FC, Kies MS, Diaz EM Jr., et al. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009; 27: 1976-1982.
  • 26
    Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008; 359: 1143-1154.
  • 27
    Kaplan EL, Meier P. Non parametric estimation from incomplete estimation. J Am Stat Assoc. 1958; 53: 457-481.
  • 28
    Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early stage nonsmall-cell lung cancer. N Engl J Med. 2006; 355: 570-580.
  • 29
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-578.
  • 30
    Kotz T, Costello R, Li Y, Posner MR. Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck. 2004; 26: 365-372.
  • 31
    Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx—induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. 2006 ASCO Annual Meeting Proceedings, part 1 [abstract]. J Clin Oncol. 2006; 24( 18S). Abstract 5517.